Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation Safety and Tolerability Trial of the Combination of s.c. Recombinant Human IL-21 (rIL-21) and Sunitinib (Phase 1) Followed by an Open Label Stratified Randomized 2-arm Trial of rIL-21 Plus Sunitinib Versus Sunitinib Alone (Phase 2a) in Subjects With Stage IV Renal Cell Carcinoma

NCT00617253 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00617253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00617253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation Safety and Tolerability Trial of the Combination of s.c. Recombinant Human IL-21 (rIL-21) and Sunitinib (Phase 1) Followed by an Open Label Stratified Randomized 2-arm Trial of rIL-21 Plus Sunitinib Versus Sunitinib Alone (Phase 2a) in Subjects With Stage IV Renal Cell Carcinoma
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
July 12, 2007
Completion date
June 30, 2008
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, renal cell carcinoma